10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
Rhea-AI Summary
10x Genomics (Nasdaq: TXG) acquired Proteintech Genomics, a division of Proteintech Group, to expand its single cell and spatial proteomics capabilities. Proteintech Genomics offers differentiated technologies such as the Human Discovery Panel, the largest antibody-based single cell protein panel, designed for integrated RNA and protein analysis within 10x-compatible workflows.
The acquisition supports 10x Genomics' multiomic strategy across its single cell, spatial and Atera platforms. Proteintech Genomics' panels are purpose-built for 10x workflows and already used to measure RNA and protein together. Transaction terms were not disclosed, and TXG expects no meaningful near-term financial impact.
AI-generated analysis. Not financial advice.
Positive
- Acquisition adds advanced proteomics technologies, including the Human Discovery Panel
- Strengthens multiomic capabilities across single cell and spatial platforms, including Atera
- Proteintech Genomics products already integrated with and used on 10x workflows
- Supports strategy to combine RNA and protein measurements in single cell experiments
Negative
- Transaction terms were not disclosed to investors
- Company expects no meaningful impact on near-term financial outlook
Market Reality Check
Peers on Argus
TXG fell 5.99% while key peers like CERT (-3.51%), OMCL (-3.61%), and GDRX (-2.59%) were also down, but no peers appeared in the momentum scanner and no same-day peer news was flagged, pointing to a stock-specific move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Aug 07 | Acquisition announcement | Positive | -4.0% | TXG agreed to acquire Scale Biosciences to enhance single cell analysis platform. |
The prior acquisition headline saw a negative price reaction, suggesting TXG’s acquisition news has previously coincided with share price weakness.
Over the last year, 10x Genomics has paired product innovation with selective acquisitions. A prior acquisition of Scale Biosciences in Aug 2025 aimed to enhance single cell capabilities but coincided with a -3.98% move. Recent news has focused on the Atera spatial platform and major collaborations like Bioptimus’ STELA project, alongside typical earnings events. Today’s Proteintech Genomics deal extends this strategy by broadening proteomics and multiomic coverage across TXG’s single cell and spatial platforms.
Historical Comparison
In the past year, TXG’s only other acquisition headline, the Scale Biosciences deal, saw a -3.98% move. Today’s -5.99% reaction to the Proteintech Genomics acquisition is somewhat more negative but directionally consistent with that history.
Acquisition strategy has focused on extending core single cell capabilities, from Scale Biosciences’ combinatorial indexing to Proteintech Genomics’ high-plex proteomic panels integrated with 10x workflows.
Market Pulse Summary
This announcement adds Proteintech Genomics’ high-plex protein panels to 10x’s single cell and spatial platforms, advancing integrated RNA–protein, or multiomic, analysis. It builds on recent launches like the Atera spatial platform and earlier acquisitions aimed at deepening single cell capabilities. With terms undisclosed and management expecting no meaningful near-term financial impact, investors may focus on how effectively these proteomic tools drive adoption, platform utilization, and future product roadmap execution.
Key Terms
proteomics medical
single cell medical
spatial applications medical
transcriptomic medical
multiomic medical
RNA medical
antibody-based medical
spatial biology medical
AI-generated analysis. Not financial advice.
Acquisition Expands 10x Genomics' Capabilities in Proteomics
The acquisition marks a strategic expansion of 10x's proteomics capabilities. Proteintech Genomics brings differentiated technologies, including its Human Discovery Panel, the largest antibody-based single cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins and transcriptomic profiles within sequencing-compatible workflows. The Human Discovery Panel is compatible with Flex chemistry, including the Flex Apex assay.
"We believe the future of biological analysis will increasingly integrate transcriptomic and proteomic information at the single cell and spatial levels," said Michael Schnall-Levin, Chief Technology Officer, Chief Strategy Officer and Founding Scientist of 10x Genomics. "The acquisition of Proteintech Genomics expands our capabilities in proteomics and supports our broader vision for richer multiomic approaches to understanding biology."
The acquisition builds on 10x's broader vision to enable multimodal biological analysis across the company's single cell and spatial platforms, including protein capabilities planned for the recently launched Atera platform.
Researchers increasingly combine transcriptomic and proteomic-based measurements to gain complementary insights into cellular identity, state and function. These approaches have helped advance discovery across immunology, oncology, neuroscience and broader cell biology research. Today, researchers often rely on multiple vendors and workflows to harmonize RNA and protein analysis in single cell experiments.
"From day one, Proteintech Genomics was built around the belief that RNA and protein measurements are most powerful when used together. Because our technologies were designed to integrate with 10x workflows, joining the 10x team feels like a natural next chapter. We are excited about the opportunity to accelerate innovation together and expand access to integrated multiomic approaches for researchers around the world," said Dr. Kristopher Nazor, CEO of Proteintech Genomics. "Single cell and spatial biology has always promised a more complete picture of cellular state - protein and RNA together, at scale, across tissues. We're finally in a position to deliver on that promise."
Proteintech Genomics' protein panels were purpose-built for 10x single cell workflows and are already used by many researchers to simultaneously analyze RNA and protein. The acquisition brings together 10x's expertise in scalable single cell and spatial biology platforms with Proteintech Genomics' advanced capabilities in protein detection.
"Biology is bigger than transcriptomics alone. Bringing scalable protein measurements into single cell and spatial biology is an important step toward richer, more predictive views of cellular state — and ultimately, virtual cell models that better reflect the complexity of living systems," said Ci Chu, Senior Vice President, AI-Enabled Discovery, Xaira Therapeutics.
For more than a decade, 10x has pioneered technologies that have transformed how scientists measure and understand biology. The acquisition of Proteintech Genomics continues that legacy, expanding the company's multiomic capabilities and reinforcing its commitment to developing breakthrough technologies that accelerate the mastery of biology and advance human health.
The terms of the transaction were not disclosed. 10x Genomics believes the transaction will not meaningfully impact its near-term financial outlook.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s acquisition of Proteintech Genomics, Inc., integration activities, potential commercial reach, potential impacts of its products and services and potential products, applications and capabilities and financial outlook. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q and 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-acquires-proteintech-genomics-a-division-within-proteintech-group-302794694.html
SOURCE 10x Genomics, Inc.